JCR manufactures a product called TEMCELL under license from Mesoblast (originally Osiris). I assume the manufacturing process is pretty consistent with Osiris' original Prochymal "recipe".
I'm pretty sure that when Mesoblast says Ryoncil has been administered to more than 1100 people, they will be including the TEMCELL recipients.
I expect this cohort to be a strong positive for the upcoming FDA decision, given that the patient numbers have been increasing strongly in Japan since first approved. This growth wouldn't be happening if doctors weren't seeing good (or great) results. And it is obviously a no-brainer risk vs reward proposition (safety vs clinical benefits).
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-324
-
- There are more pages in this discussion • 531 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |